Overview

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib